Literature DB >> 3093966

Varicella: complications and costs.

S R Preblud.   

Abstract

Varicella (chickenpox) has long been considered a benign, inevitable disease of childhood. Complications are generally mild and rarely severe, and virtually every individual is infected by adulthood. Infection is associated, however, with a high risk of serious complications in certain high-risk groups, such as leukemic children. Concerns about the severity of varicella in this population have led to the development and testing of a live, attenuated vaccine. Because of the favorable results thus far available, the vaccine may soon be licensed for use in high-risk individuals. The fact that a vaccine may soon be available has led to an increased interest in the potential benefits of a childhood varicella vaccine program. The costs associated with varicella infection in normal persons without a varicella vaccination program have been estimated to be approximately $400 million, 95% of which is the cost of caring for a child at home. Vaccination of normal 15-month-old children with a safe and effective vaccine with long-lasting immunity could reduce the cost by 66% and result in a savings of $7 for every dollar spent on the vaccination program. This assumes that vaccine would be administered only once with measles, mumps, and rubella vaccine, that there would be no increase in the number of varicella cases in older persons who are at increased risk for complications, and that there would be no deleterious effect on the occurrence and severity of herpes zoster.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1986        PMID: 3093966

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  38 in total

1.  Varicella vaccination. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2001-06-26       Impact factor: 8.262

Review 2.  Varicella vaccination--a critical review of the evidence.

Authors:  S A Skull; E E Wang
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

Review 3.  25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.

Authors:  M Takahashi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Pharmacoeconomics of immunisation: a review.

Authors:  R van den Oever; D de Graeve; B Hepp; A Stroobant; D Walckiers; V Van Casteren; F Van Loock; G Ducoffre; J Dewatripont; P Jacques
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

5.  Managing childhood chickenpox: cost implications.

Authors:  P A Brunell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 6.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

7.  Use of a reformulated Oka strain varicella vaccine (SmithKline Beecham Biologicals/Oka) in healthy children.

Authors:  A Y Tan; C J Connett; G J Connett; S C Quek; H K Yap; F Meurice; B W Lee
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

Review 8.  Economic evaluations of varicella vaccination programmes: a review of the literature.

Authors:  Nancy Thiry; Philippe Beutels; Pierre Van Damme; Eddy Van Doorslaer
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Age-specific incidence of chickenpox.

Authors:  R Finger; J P Hughes; B J Meade; A R Pelletier; C T Palmer
Journal:  Public Health Rep       Date:  1994 Nov-Dec       Impact factor: 2.792

10.  Burden of chickenpox on families: A study in Quebec.

Authors:  P De Wals; M Blackburn; M Guay; G Bravo; D Blanchette; M Douville-Fradet
Journal:  Can J Infect Dis       Date:  2001-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.